Larimar Therapeutics, Inc.
No SEC Form 4 filings for $LRMR in the last 30 days.
See all $LRMR insider activity →Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels,
Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.
Investing.com reports Nasdaq up about 1% as chip stocks extend a rebound. SanDisk Corp-Exch (SNDK) rose 12.28% and Lam Research (LRCX) gained 6.95%, alongside other chip-related movers. Costco reported June net sales of $29.24B, up 10.6%. Ionis (IONS) fell after its heart disease trial missed a primary endpoint.
Over the past 7 days, alphai's AI scored 1 news story mentioning LRMR (Larimar Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LRMR coverage spans financial news, earnings and regulation.
New regulatory and clinical execution milestones plus updated cash runway into Q3 2027 can shift probability-weighted approval timing and financing risk for LRMR.
BLA progress and FDA acceptance of a surrogate endpoint are near-term catalysts for LRMR, but open-label efficacy and safety concerns limit conviction.
LRMR’s move is presented without any accompanying LRMR-specific news in the text.
Insider buying is a near-term sentiment tailwind, but it is not a fundamental catalyst like trial data or guidance.
This is a disclosed insider buy, but it is not a fundamental catalyst like earnings, trial data, or financing.
alphai scores every news story that mentions LRMR with an AI model for sentiment and relevance, and aggregates insider trades from Larimar Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels,
4 min readLarimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.
4 min readInvesting.com reports Nasdaq up about 1% as chip stocks extend a rebound. SanDisk Corp-Exch (SNDK) rose 12.28% and Lam Research (LRCX) gained 6.95%, alongside other chip-related movers. Costco reported June net sales of $29.24B, up 10.6%. Ionis (IONS) fell after its heart disease trial missed a primary endpoint.
4 min readLarimar Therapeutics Inc (NASDAQ:LRMR) shares rose 15.5% after director Thomas Edward Hamilton bought 50,000 shares, according to an SEC Form 4. The weighted average price was $3.3378, with trades between $3.33 and $3.35. Hamilton now owns 714,798 shares directly, plus 159,433 indirectly via Post Edison, LLC.
2 min readHamilton Thomas Edward purchased 50,000 shares of Larimar Therapeutics, Inc. (LRMR) at $3.34 ($0.17M total) on 2026-07-06.
1 min readA roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.
2 min readLarimar Therapeutics said it will host an investor webcast on Monday, June 29, 2026 at 7:45 a.m. ET to update on its Nomlabofusp program for Friedreich’s ataxia. The company plans to discuss a regulatory update and data from an ongoing Phase 2 long-term open-label study. Larimar also outlined use of its intracellular delivery platform for other rare diseases.
2 min readAnalysts issued multiple rating and price-target changes across Wall Street. JPMorgan upgraded Openlane to overweight and raised its Dec 2026 PT to $38; UBS upgraded Ecolab to buy with a $325 PT; Barclays upgraded SanDisk to overweight. Micron’s PT was raised to $1,175 by Barclays. JPMorgan upgraded FedEx to overweight ahead of late-June earnings.
6 min readLarimar Therapeutics director Joseph Truitt was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the date of the next annual meeting, contingent on his continued service on the Board of Directors. Following this grant, Truitt directly holds 55,150 stock options.
2 min readLarimar Therapeutics director Frank E. Thomas was granted 55,150 stock options as equity compensation, with an exercise price of $3.33 per share. These options vest on the earlier of May 19, 2027, or the date of the next annual stockholder meeting, contingent on his continued service on the board. This transaction is considered a routine, service-based incentive rather than an open-market trade.
2 min read
